Methods of inhibiting viral replication and improving T cell function employing soluble Tim-3 inhibitors
US-9416165-B2 · Aug 16, 2016 · US
Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy
US11116838B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11116838-B2 |
| Application number | US-201615546740-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 28, 2016 |
| Priority date | Jan 29, 2015 |
| Publication date | Sep 14, 2021 |
| Grant date | Sep 14, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.
First claim
Opening claim text (preview).
The invention claimed is: 1. A composition for generating hTERT-specific CD3+CD8+ T cells displaying double release of the cytokines IFNγ and TNFα in a subject in need thereof, comprising: a) a monoclonal TIM-3 antibody or a monoclonal LAG-3 antibody, and b) a nucleic acid molecule comprising a nucleotide sequence encoding a synthetic hTERT antigen. 2. The composition of claim 1 wherein the synthetic antigen is an isolated DNA that encodes for the antigen. 3. The composition of claim 1 , further comprising a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
wherein the target is cancer · CPC title
characterised by the dose, timing or administration schedule · CPC title
DNA (RNA) vaccination · CPC title
against CD28 or CD152 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11116838B2 cover?
- Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor. Also disclosed herein is a method for enhancing an immune response in a subject. The method may comprise administering the vaccine to the subject in need thereof.
- Who is the assignee on this patent?
- Univ Pennsylvania, Inovio Pharmaceuticals Inc, Weiner David, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).